Published in Cancer Weekly, March 9th, 2004
Total sales for the 2003 fourth quarter were $4.2 million, up 13% from total sales of $3.7 million for the year-earlier period.
The net loss for the fourth quarter of 2003 was $2.2 million, or a $0.12 loss per share, compared to a net loss of $3.1 million, or $0.20 loss per share, for the fourth quarter of 2002. Operating expenses declined 15% in the 2003 fourth quarter to $4.8 million from $5.7 million in the prior year...
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Cancer Weekly
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.